FacebookXInstagramTelegram
WhatsApp! 020-122-280-6824

The main category of All News Articles.

You can use the search box below to find what you need.

[wd_asp id=1]

5 11, 2025

Oil Price Forecast – Crude Oil Prices Drop to $59 as WTI, Brent Extend Losses Amid Weak Demand

By |2025-11-05T21:47:20+02:00November 5, 2025|Forex News, News|0 Comments


Crude Oil Prices Today: WTI (CL=F) and Brent (BZ=F) Extend Losses as Demand Weakness Deepens and Global Inventories Rise

WTI and Brent Futures Retreat Amid Mounting Demand Concerns

Crude oil prices slipped further on Wednesday, with West Texas Intermediate (CL=F) futures down 1.27% to $59.79 per barrel, while Brent (BZ=F) dropped 1.15% to $63.70 — marking one of the weakest weekly starts since mid-August. Traders cited fragile demand in Asia and renewed signs of oversupply as the primary drag, with the U.S. dollar’s resilience adding additional downward pressure on dollar-denominated commodities.

Data from the American Petroleum Institute (API) revealed an unexpected 6.5-million-barrel build in U.S. crude inventories for the week ending October 31, amplifying bearish sentiment across the futures curve. As of early November, U.S. stockpiles have increased by 3.6 million barrels year-to-date, while gasoline inventories dropped 5.65 million barrels, highlighting a diverging picture between refined product consumption and crude accumulation. The Department of Energy (DoE) confirmed a 500,000-barrel addition to the Strategic Petroleum Reserve (SPR), raising reserves to 409.6 million barrels — a symbolic step in the ongoing effort to rebuild post-Biden era drawdowns.

Supply-Side Friction: OPEC+ Discipline Tested as Global Output Expands

While OPEC+ has paused planned output hikes until early 2026 following its modest December adjustment, the group’s production restraint is being overshadowed by increasing non-OPEC supply. The U.S. Energy Information Administration (EIA) reported domestic output at 13.64 million barrels per day (bpd) — a record level and 109,000 bpd higher than January 2025. Meanwhile, Kazakhstan’s Tengiz field maintenance trimmed national production by 10%, offering only temporary support to prices.

At the same time, Iraq canceled Lukoil cargoes due to tightened U.S. sanctions on Russian oil firms, disrupting trade flows and complicating OPEC+ coordination. Nevertheless, traders remain skeptical that these geopolitical disruptions will offset the structural oversupply building in global shipping data. According to Gunvor Group co-founder Torbjörn Törnqvist, “unprecedented volumes” of oil are now stored on tankers as sanctions on Russia and Iran reroute millions of barrels into “floating storage,” creating what analysts at Mercuria estimate to be a 1–2 million bpd surplus heading into Q1 2026.

ADNOC and Long-Term Oil Outlook: Demand Above 100 Million BPD Beyond 2040

Despite the near-term weakness, Abu Dhabi National Oil Company (ADNOC) executives reaffirmed a structurally bullish long-term view. Speaking at ADIPEC 2025, ADNOC Upstream CEO Musabbeh Al Kaabi projected that global oil demand will stay above 100 million barrels per day well into the 2040s, driven by aviation, petrochemical growth, and energy-intensive industries like AI data centers. The UAE’s production capacity stands at 4.85 million bpd, targeting 5 million bpd by 2027, supported by expansion at the Upper Zakum field, which could hit 1.5 million bpd ahead of schedule.

ADNOC’s chief, Sultan Al Jaber, emphasized that the world requires $4 trillion in annual investment in grids, data centers, and new energy infrastructure, underscoring the interplay between fossil and renewable demand. He noted that while renewables are expected to double by 2040, oil and LNG will remain central, with LNG projected to grow 50% and jet fuel demand up 30% over the same period. This long-term foundation offers critical support to producers with low-cost, low-emission barrels, a group in which the UAE, Saudi Aramco, and ExxonMobil remain dominant.

Geopolitical Disruptions and Tanker Storage Surge

The sanctions-driven reshuffling of crude trade is now producing measurable distortions. Commodity traders report a rapid increase in “oil on water” volumes, estimated at over 200 million barrels, as sanctioned crude from Russia and Iran struggles to find destination markets. Gunvor and Mercuria both warn that if sanctions are lifted suddenly, a flood of delayed cargoes could overwhelm markets, driving Brent temporarily below $60 per barrel.

At the same time, Libya announced a new onshore oil discovery, while Nigeria reaffirmed its target of 2 million bpd production by 2027. Meanwhile, Eni (BIT:ENI) and Petronas formed a $15 billion upstream joint venture across Malaysia and Indonesia, further expanding Asian supply capacity. The balance between sanctioned oil constraints and fresh project ramp-ups is therefore delicate — but tilting toward oversupply for now.

U.S. Energy Data: Inventories Rise, Refining Margins Narrow

The WTI curve has flattened notably, with front-month spreads near −$0.35, indicating weak near-term demand. U.S. refiner margins have slipped below $17 per barrel, down from over $25 earlier this quarter, reflecting narrowing profits from gasoline and diesel. The Mars US blend fell 1.34% to $70.71, and Louisiana Light dipped to $62.79, confirming pressure on Gulf Coast benchmarks.

Gasoline futures at $1.911 per gallon and natural gas (NG=F) at $4.256/MMBtu (−2.0%) both signal declining consumer energy appetite. The OPEC basket sits at $65.43 (−1.59%), below the key $67.50 comfort threshold that most cartel members use as their fiscal breakeven reference.

ADNOC, Exxon, and Aramco Lead Output Expansion Strategy

In contrast to the weakening spot market, Saudi Aramco (TADAWUL:2222) reported a Q3 profit of $28 billion, up 6% quarter-on-quarter, supported by higher upstream volumes and improved operational efficiency. ExxonMobil (NYSE:XOM) and Chevron (NYSE:CVX) also exceeded forecasts, with Exxon confirming that Upper Zakum output expansion remains on track, and Chevron’s Hess acquisition boosting Q3 output beyond expectations.

Energy supermajors continue to consolidate upstream exposure while trimming exposure to high-cost, carbon-intensive projects. This dynamic is creating a bifurcated energy market — integrated producers thriving, while smaller shale drillers retreat as prices slide below $60.

Analyst View: Oil Market in Technical Downtrend but Long-Term Support Intact

From a technical standpoint, WTI (CL=F) faces resistance near the 50-day EMA ($62), while Brent (BZ=F) remains capped around $65–$66. Momentum oscillators confirm downside bias, with RSI at 38 and MACD negative, signaling risk of further weakness toward $58.50–$57.90 short-term.

However, the longer-term structure suggests stabilization within a $5 range, as physical fundamentals limit deeper collapses. Short-term rallies are viewed as selling opportunities, yet long-term investors could begin accumulating at sub-$60 levels — especially if geopolitical disruptions or OPEC+ interventions materialize. The market’s immediate trajectory remains bearish, but structural demand exceeding 100 million bpd beyond 2040 underpins a long-term bullish thesis.

Verdict: Short-Term Bearish, Long-Term Accumulation Zone

The TradingNews.com analysis categorizes current oil market dynamics as short-term bearish, long-term bullish accumulation zone. Near-term downside remains possible toward $58 WTI / $62 Brent, driven by weak Asian demand, strong dollar pressure, and bloated inventories. Yet, consistent producer discipline and ADNOC’s long-term projections suggest eventual rebalancing.
Recommendation: HOLD for institutional investors; BUY on dips below $58 WTI for long-term exposure.

That’s TradingNEWS





Source link

Read More
5 11, 2025

3 things a celeb doctor adds to his tea to support longevity

By |2025-11-05T21:19:17+02:00November 5, 2025|Dietary Supplements News, News|0 Comments


Coffee, meet your match.

Every morning, Dr. Nicholas Perricone starts his day with a cup of green tea supercharged with three powerhouse ingredients that he says boost energy, slim the body and promote longevity.

“I’ve always believed that simple, consistent habits add up to profound results,” the 77-year-old celebrity nutritionist and dermatologist told The Post.

Dr. Nicholas Perricone has been working in the dermatology and nutrition fields for more than three decades. Getty Images for East Hampton Library

“This morning ritual is my way of stacking science-backed ingredients to support both immediate clarity and long-term health,” Perricone said. “It’s not about a quick fix, but about creating daily practices that nurture the body and mind over decades.”

The anti-aging guru — who has won a following among stars like Jennifer Lopez, Christie Brinkley, and Kate Hudson — spilled the tea on his regimen in his new book, “The Beauty Molecule: Introducing Neuroceuticals, the Breakthrough for Ageless Beauty.”

“I’ve tried just about everything in the name of health over the years, but this simple routine is something I look forward to every morning,” Perricone said in an interview. “It’s warming, nourishing and restorative.”

But even before the extras, Perricone said green tea packs plenty of power on its own.

The beverage “provides a steady, calm energy” without the jitters of coffee, thanks to an amino acid called L-theanine, he explained, which sharpens focus and cognitive function while keeping the mind relaxed.

Green tea is also loaded with antioxidants, including polyphenols called catechins, which help protect cells from free radical damage and reduce oxidative stress.

That has been linked to a lower risk of chronic conditions like cancer, heart disease and stroke, along with less inflammation and better insulin sensitivity — a key factor in staving off type 2 diabetes.

Green tea can also rev up metabolism, making it easier to shed extra body fat.


3 things a celeb doctor adds to his tea to support longevity
While green tea contains caffeine, it provides a calmer energy boost than coffee. Ekaterina Pokrovsky – stock.adobe.com

Ingredient #1: C8 medium-chain triglycerides

Perricone then take things a step further. Instead of milk or sugar, he adds a splash of C8 medium-chain triglycerides (MCTs).

Found naturally in coconut and palm kernel oil, these fats have smaller molecules than most others, so the body digests them faster and converts them into energy more quickly.

Perricone said C8 MCTs help “fuel his brain,” and research suggests they may also support weight management and gut health.

Ingredient #2: olive oil

Next up: a teaspoon of extra-virgin olive oil, which Perricone said activates the body’s sirtuin genes, which play a key role in cellular repair, rejuvenation and longevity.

Studies also link extra-virgin olive oil to stronger heart health, better digestion, stroke prevention, sharper cognitive function and even potential protection against Alzheimer’s disease.

Ingredient #3: cinnamon

Finally, Perricone sprinkles in ¼ teaspoon of cinnamon, which stabilizes blood sugar and reduces inflammation. It may also boost memory, aid weight loss and support the immune system.

“It’s a small ritual, but it sets the tone for a day of focus and balance,” Perricone said. “Beyond science, it’s become a meditative pause … a reminder that taking care of ourselves can be both effective and enjoyable.”



Source link

Read More
5 11, 2025

Bitcoin price prediction: BTC above $103K today: Bitcoin is rising sharply above $103K today: Why is BTC bouncing back again? Will the correction last? Latest Bitcoin price prediction is here

By |2025-11-05T21:13:17+02:00November 5, 2025|Crypto News, News|0 Comments

Bitcoin price is climbing again. After plunging below $100,000 on Tuesday for the first time since June, Bitcoin (BTCUSD) has rebounded sharply above $103,000, rising nearly 1.99% in the last 24 hours. It’s now trading around $103,494, up about $2,025 from yesterday’s close. The recovery comes as traders digest a brutal week that saw Bitcoin tumble over 20% from its all-time high of $126,296 set just a month ago. The daily range between $98,950 and $104,026 shows how volatile the market remains. Bitcoin’s total market cap now sits near $2.04 trillion, with $793.8 million in trading volume over the past 24 hours.

But beneath the rebound lies a deeper concern — long-term holders are selling big. According to 10x Research, veteran investors have offloaded around 400,000 BTC in the last month, worth nearly $45 billion. Markus Thielen, the firm’s head of research, warned that this “massive exodus” has left the market unbalanced. “Conviction among long-term holders is eroding,” he said, adding that the selling pressure could continue well into next year.

Data from K33 Research shows over 319,000 Bitcoin have been reactivated from wallets dormant for six to twelve months — a clear sign of profit-taking. “While some reactivation stems from internal transfers, much reflects real selling,” said Vetle Lunde, head of research at K33. The pattern suggests many investors are locking in gains as prices stall, with confidence slipping after months of strong momentum.

Unlike the October crash, when $19 billion in leveraged positions were wiped out, this selloff has been driven mainly by spot market selling. In the past 24 hours, only $2 billion in crypto positions were liquidated — modest compared to prior washouts. This means the pressure is coming from investors willingly exiting, not from margin calls. Meanwhile, open interest in Bitcoin futures remains muted, and options traders are loading up on put contracts targeting $80,000, signaling expectations of more downside.

Thielen said the key driver now is the imbalance between sellers and buyers. “The whales are just not buying,” he noted, pointing out that wallets holding 100–1,000 BTC have sharply cut accumulation. Institutional demand, which once cushioned Bitcoin’s pullbacks, has also cooled. With the 50-day moving average around $113,379 and the 200-day near $109,952, Bitcoin remains technically in a bearish zone.


Looking ahead, Thielen expects the unwind to last until spring 2026, similar to the 2021–2022 bear market, when over 1 million BTC were sold by large holders over several months. He doesn’t expect a collapse but sees room for a further decline toward $85,000, his maximum downside target. “We could see Bitcoin consolidating or drifting slightly lower from here before stability returns,” he said. Despite the fear, institutional interest hasn’t vanished completely. Some analysts argue this reset could strengthen Bitcoin’s long-term setup, allowing a healthier base before the next rally. For now, all eyes are on the $100,000 mark — the new psychological floor. Holding that level could mean the correction is near its end. But slipping below it again might trigger the next leg of this crypto downturn. Bitcoin price prediction: The near-term outlook suggests cautious consolidation around $100K–$105K, with upside resistance near $110K and a potential downside floor around $85K if selling continues. The next few weeks will reveal whether Bitcoin’s bounce is the start of recovery or just a brief relief rally before another wave of pressure hits.

Bitcoin price rebounds but market remains fragile

Bitcoin (BTCUSD) rose 1.99% to around $103,494, recovering from a sharp drop below $100,000 earlier this week. The world’s largest cryptocurrency gained about $2,025 in the past 24 hours after Tuesday’s 7.4% plunge — its steepest fall since June. The day’s trading range hovered between $98,950 and $104,026, showing the ongoing market volatility.

At current levels, Bitcoin’s market capitalization stands near $2.04 trillion, with $793.8 million in trading volume over the last 24 hours. The digital asset opened at $101,468, the same as its previous close, suggesting cautious sentiment among traders.

Long-term holders dump $45 billion in Bitcoin

The latest correction wasn’t triggered by leverage this time. Instead, it’s being driven by long-term Bitcoin holders unloading nearly 400,000 BTC, worth around $45 billion, over the past month. According to Markus Thielen of 10x Research, this wave of selling has left the market “unbalanced.”

Data from K33 Research shows that 319,000 Bitcoin have been reactivated in recent weeks, mostly from wallets inactive for six to twelve months — a clear sign of profit-taking. “While some reactivation stems from internal transfers, much reflects real selling,” said Vetle Lunde, head of research at K33.

Why Bitcoin fell below $100,000

Bitcoin dropped below $100,000 for the first time since mid-June, marking a 20% decline from its record high of $126,296 reached last month. The pullback follows a broader “risk-off” shift across financial markets as investors reassess inflation and rate-cut expectations.

Unlike October’s crash, which was fueled by forced liquidations, the current slide stems from steady selling in the spot market. Around $2 billion in crypto positions were liquidated over the last day — far below the $19 billion wiped out in October’s derivatives-driven crash.

Open interest in Bitcoin futures remains subdued, while options traders are increasingly betting on downside risk, with many targeting the $80,000 level through put contracts.

Whale activity points to fading confidence

According to Thielen, Bitcoin’s direction now depends on how quickly new buyers can absorb the coins long-term holders are selling. “Mega whales,” who hold between 1,000 and 10,000 BTC, started reducing their exposure months ago. Institutional buyers have slowed down, and accumulation among wallets holding 100–1,000 BTC has dropped sharply.

“The whales are just not buying,” Thielen said, warning that this imbalance could keep pressure on prices.

Bitcoin’s 50-day moving average sits at $113,379, while the 200-day average is around $109,952 — both above current prices, signaling a bearish setup. Thielen expects the ongoing unwind to continue well into spring 2026, possibly mirroring the 2021–2022 bear cycle, when over 1 million BTC were sold across a year.

While he doesn’t expect a crash, Thielen sees potential for further declines, with a maximum downside target of $85,000. “We could consolidate and drift a bit lower from here,” he said.

Despite the selloff, institutional interest remains firm, suggesting the correction may represent a healthy reset rather than a deeper collapse. Traders are closely watching whether Bitcoin can hold above $100,000, which may define the next trend in the crypto market.

Source link

Read More
5 11, 2025

Learn About Nonhormonal Hot Flash Treatment

By |2025-11-05T20:50:44+02:00November 5, 2025|Fitness News, News|0 Comments

During perimenopause and menopause, hot flashes can happen anytime day or night. Heat rises up through your body. Your face, neck and chest might become red, and you may start sweating. And it’s more than just a pain in the neck – hot flashes, especially when they’re severe, can be really disruptive. In fact, about 3 in 10 women with hot flashes have them so badly they need treatment.

Hot flashes — one of the two vasomotor symptoms (VMS) of menopause — happen when a hormone in your body called estrogen begins to drop. Estrogen affects the part of your brain that controls body temperature. Up to 8 out of 10 pre- and postmenopausal women experience hot flashes, and they can last between seven and 10 years — and Black and Hispanic women often experience hot flashes for even longer.

The most effective treatment for hot flashes is hormone therapy (HT). But not all women can take hormonal medication for a variety of reasons. “This includes women who’ve had estrogen-sensitive breast or uterine cancer, heart attack, stroke, blood clots or pulmonary embolisms,” said JoAnn Pinkerton, M.D., medical director of Midlife Health Center and member of HealthyWomen’s Women’s Health Advisory Council. Other women may choose not to take HT for personal reasons.

Now, these women have a new option. In October, the U.S. Food and Drug Administration (FDA) approved a new hormone-free drug called elinzanetant to help treat moderate-to-severe hot flashes. It joins fezolinetant, which was approved for the same indication in 2023. With more nonhormonal treatments available than ever before, it can be hard to know which one is right for you.

Here’s what you need to know about hot flash treatments.

Nonhormonal hot flash medications

Two new hormone-free medications target the temperature control center of the brain to reduce hot flashes. The medications stop hot flashes by counteracting the drop in estrogen by binding to and blocking the parts of your brain that allow your temperature to go up when your hormone level drops.

Elinzanetant (brand name: Lynkuet): In clinical studies, elinzanetant reduced hot flashes by 73% and also helped women sleep better.

Common side effects of elinzanetant:

  • Drowsiness
  • Headache
  • Abdominal pain

Fezolinetant (brand name: Veozah): Has been shown to improve mood, sleep and overall quality of life.

Common side effects of fezolinetant include:

  • Stomach pain
  • Insomnia
  • Elevated liver enzymes

It’s always important to talk to your HCP about whether any prescription medication is right for you. Elinzanetant and fezolinetant can interfere with certain medications, so it’s important to tell them what else you’re taking.

Both of these non-hormonal hot flash treatments are processed through your liver, so you need to get your liver checked every three months if you take them. And for fezolinetant, you need to have a baseline liver level recorded before you start. As with any medication, certain people should not take these drugs.

Elinzanetant and fezolinetant can also be expensive and may not be covered by insurance, but you may be able to find coupons and savings opportunities on their websites or by asking your pharmacist.

Off-label medications

Some medications not specifically meant for hot flashes have been shown to help reduce VMS symptoms. Pinkerton said that more research is needed to understand why, but these medications seem to have an effect on the temperature regulator in your brain.

Antidepressants including SSRIs and SNRIs reduce hot flashes in up to 64% of women. These can be a good choice for women who struggle with depression or anxiety and have VMS symptoms.

Side effects of SSRIs and SNRIs can include:

  • Nausea
  • Gastrointestinal issues
  • Weight changes
  • Headache
  • Sexual dysfunction

Gabapentin (brand names: Horizant, Gralise and Neurontin) is a nerve-blocker that can help ease the severity of hot flashes by up to 51%. Because it can make you drowsy, it’s often prescribed for women with hot flashes who also have difficulty sleeping and because it’s a nerve blocker, it can also be an option for women who have neuropathic pain.

Side effects of gabapentin can include:

  • Dizziness
  • Coordination difficulties
  • Weight gain
  • Swelling
  • Gastrointestinal issues.

Oxybutynin (brand name: Ditropan) is a medication prescribed for overactive bladder that can reduce hot flashes by up to 86%. This may be a good choice for women who have both urinary issues and hot flashes.

Side effects of oxybutynin include:

  • Dry eyes
  • Dry mouth
  • Urine retention
  • Dizziness
  • Drowsiness
  • Constipation
  • Nausea

Supplements for hot flashes

Over-the-counter supplements for hot flashes contain vitamins, minerals, amino acids and other ingredients that can help reduce symptoms. Pinkerton said these options may help women with mild-to-moderate symptoms, but they won’t help with severe symptoms. She also warned that they are not FDA-approved, which means they aren’t regulated, may not be proven to help, and may contain contaminants.

EstroG-100 is a supplement rooted in Asian folk medicine. In one study, EstroG-100 reduced hot flashes after 12 weeks of use. It may also help with other menopause symptoms, including sleep issues.

S-equol is a soy-based product that may benefit some, but not all, menopausal women. More studies are needed to find out how effective it is.

Black cohosh is an herbal supplement native to North America that is thought to reduce symptoms of menopause. There is limited evidence to support its use. It can cause mild side effects and interact with certain drugs. It’s important to be extremely cautious if using this herbal remedy.

Red clover is an herb from southeast Europe that has been traditionally used to treat upper- respiratory tract infections. There is some evidence that red clover can help menopausal symptoms, but more clinical studies are needed.

Lifestyle changes for hot flashes

Making certain lifestyle changes can help with the severity and number of hot flashes you have. Pinkerton suggested moderate exercise, getting at least seven hours of sleep each night, and eating a Mediterranean diet high in protein, fruits and vegetables. You should also quit smoking and limit alcohol and caffeine.

An individualized approach based on your symptoms is the best way to address hot flashes.

If your symptoms are mild, Pinkerton said over-the-counter options could work. But if your hot flashes are disrupting your work, sleep or relationships, it’s a good idea to schedule an appointment with your HCP. “Make sure that someone’s listening to you, and that they’re offering evidence-based therapies,” she said.

From Your Site Articles

Related Articles Around the Web



Source link

Read More
5 11, 2025

Ex-TRON Lead Hunter Rogers Joins TeraHash as Co-Founder to Drive Bitcoin-Native Yield to DeFi | Currency News | Financial and Business News

By |2025-11-05T19:51:15+02:00November 5, 2025|News, NFT News|0 Comments


Newark, Delaware, USA, November 5th, 2025, FinanceWire

Rogers brings institutional partnerships and strategic capital expertise to accelerate the adoption of the hashrate-backed Bitcoin yield protocol.

TeraHash, the Bitcoin-native yield layer unlocking $20B+ in annual mining revenue for DeFi, today named Hunter Rogers as Co-Founder. Rogers joins from TRON DAO, where he led ecosystem development and investment strategy for one of the world’s largest blockchain networks. At TRON he closed multimillion-dollar partnerships and helped scale institutional adoption.

The appointment strengthens TeraHash’s leadership as the protocol prepares for mainnet. The project has already attracted more than 8 million users during its pre-launch phase.

Strategic Leadership for Bitcoin’s Yield Infrastructure

At TeraHash, Rogers will lead ecosystem partnerships, institutional outreach, and community growth initiatives. His brief is to position TeraHash as the institutional standard for Bitcoin mining yield, which delivers staking rewards in crypto (up to 50% APY) through liquid and composable DeFi infrastructure.

“Bitcoin’s next evolution lies in making its $20 billion annual mining yield accessible through transparent, on-chain infrastructure,” said Hunter Rogers, Co-Founder of TeraHash. “TeraHash is building that bridge, as it transforms physical hashrate into liquid, composable, and accessible yield primitives for institutions and individuals alike. I’m excited to help scale this ecosystem globally, as well as establish TeraHash as the definitive Bitcoin yield layer for DeFi.”

Proven Track Record in Blockchain Infrastructure

Before joining TeraHash, Rogers was Senior Ecosystem Development and Investment Lead at TRON DAO, where he:

  • Built global partnerships across institutions, protocols, and enterprises;
  • Closed multimillion-dollar deals to expand TRON’s footprint;
  • Directed capital strategy while scaling community growth to millions;
  • Scaled community growth to millions of users worldwide.

Rogers brings deep expertise in blockchain infrastructure, capital strategy, and ecosystem development. He completed Executive Education at The Wharton School, specializing in Mergers & Acquisitions, Corporate Development Strategies, and Artificial Intelligence for Business. His experience covers DePIN infrastructure, institutional tokenization, and AI integration. These are competencies directly relevant to TeraHash’s mission of building scalable, institutional-grade Bitcoin yield infrastructure.

Timing Bitcoin DeFi’s Inflection Point

Rogers joins as Bitcoin DeFi gains momentum. The rise of Ordinals, BRC-20s, and growing institutional interest have accelerated activity in BTCFi. Still, a native, composable yield product for Bitcoin mining has been missing.

TeraHash addresses that gap by issuing $THS tokens that represent real mining power. Users stake $THS (each token = 1 TH/s) and receive daily Bitcoin rewards without the need to run miners or handle operations. The protocol is composable with DeFi, and it enables integrations with lending platforms, yield aggregators, and trading venues.

Market-Leading Traction and Infrastructure

TeraHash has shown early traction:

 • Has secured $300M+ in equipment contracts to lock supply;

• Attracted 8M+ users during pre-launch;

• Recorded ~50% historical APY (7x higher than Ethereum staking).

The protocol is completing a Strategic Round for institutional participants and is on track for mainnet launch.

About TeraHash

TeraHash is the Bitcoin-native yield layer bringing institutional-grade mining yields to DeFi. By tokenizing real mining hashrate into liquid staking positions, TeraHash enables users to earn up to 50% yearly Bitcoin yields in rewards without operational complexity. The protocol features a dual-token model: $THS (yield token representing hashrate) and $HASH (governance and yield amplification token with 21M fixed supply). TeraHash is backed by strategic partners & advisors, and leading protocols & blockchain infrastructure providers.

For more information, users can visit TeraHash.xyz

Contact

TeraHash
pr@terahash.xyz



Source link

Read More
5 11, 2025

XAU/USD extends its consolidative phase below $4,000

By |2025-11-05T19:46:21+02:00November 5, 2025|Forex News, News|0 Comments


XAU/USD Current price: $3,98

  • Encouraging United States private sector data underpinned the US Dollar.
  • US Democrats notched victories in multiple states as the shutdown continues.
  • XAU/USD consolidates within familiar levels with the risk skew to the downside.

Gold traded within a well-defined range throughout the first half of Wednesday, now hovering around $3,980 per troy ounce in the American session. The lack of a clear catalyst kept investors in cautious mode, although the US Dollar (USD) retained its positive tone across the FX board.

Finally, the United States (US) released the ADP Employment Change survey, which showed that the private sector added 42,000 new job positions in October, better than the upwardly revised -29,000 posted in September.

Additionally, the ISM Services Purchasing Managers’ Index (PMI) improved to 52.4 in October, much better than the previous 50 or the expected 50.8. Upon closer examination, the Prices Paid Index, which tracks inflation, increased to 70.0 from 69.4, while the Employment Index rose to 48.2 from 47.2. Finally, the New Orders Index rose to 56.2, from 50.4.

Aside from that, speculative interest kept a close eye on the US elections. Democrats notched victories in multiple states, not good news for President Donald Trump, who blamed GOP losses on the ongoing shutdown. Indeed, California, Virginia, and most likely New Jersey have new Democratic governors, while New York City voted for progressive Zohran Mamdani and his affordability platform.

Meanwhile, Wall Street reversed Tuesday’s losses, and the three major indexes trade in the green after the positive surprise provided by data, although gains are modest. Overall, market players seem cautiously optimistic and willing to continue betting on the Greenback.

XAU/USD short-term technical outlook

In the 4-hour chart, the XAU/USD pair is currently trading at around $3,980, up $19 for the day. From a technical point of view, a bearish 20 Simple Moving Average (SMA) at $3,986 contained advances, while converging with a marginally bullish 200 SMA, the latter at $3,996. Further up, the 100 SMA acts as resistance at $4,095.Technical indicators, in the meantime, reflect the lack of directional strength. The Momentum indicator recovered but remains below its midline, while the Relative Strength Index (RSI) indicator holds flat at 48.

In the daily chart, the XAU/USD is developing below the 20-day Simple Moving Average, which currently stands at $4,084. However, the pair is above the longer ones with the 100-day SMA at $3,602 and the 200-day SMA at $3,365 acting as mid-term dynamic supports. At the same time, the Momentum indicator plunged below its midline, and maintaining its downward strength, while the RSI indicator remains directionless at around its 50 level, skewing the risk to the downside without confirming an imminent slide.

(This content was partially created with the help of an AI tool)



Source link

Read More
5 11, 2025

Drops to Find Support (Video)

By |2025-11-05T19:33:24+02:00November 5, 2025|Forex News, News|0 Comments

  • The U.S. dollar slipped against the yen on Tuesday, testing support near ¥153 after an early rally faded.
  • Despite short-term softness, the broader uptrend remains intact as rate differentials continue to favor the dollar.

You can see that the U.S. dollar initially tried to rally against the Japanese yen during trading on Tuesday, but it is struggling. We did fall enough to go looking to the ¥153 level. The ¥153 level is an area that had been a significant resistance barrier and now could end up being a significant support level based on market memory.

If we do in fact see a little bit of a bounce, then it’s likely that the overall uptrend continues, and that does make a certain amount of sense considering that the interest rate differential continues to favor the greenback. The Bank of Japan will more likely than not have to stay somewhat loose with monetary policy, and the Federal Reserve has recently stated at the FOMC press conference that they are not ready to cut rates automatically, at least in December. So, we’ll just have to wait and see how this plays out.

This is a market that won’t go straight up in the air forever, but I do think it goes higher over the longer term. A little bit of a drop and then a bounce opens up the possibility of value hunters coming in and picking up the U.S. dollar, jumping into this overall trend. If we break down below the ¥153 level, then the ¥152 level becomes support as well.

I Won’t Short Here

I have no interest in shorting this pair. The Japanese yen itself is weak against most currencies, and I think the U.S. dollar won’t be any different. All things being equal, I do think that we are going higher. We will probably go looking to the ¥155 level next, but it is going to be choppy and positive overall as the market has been more or less a grind to the upside. Ultimately, this is a market that I think is going to continue to look for value on dips and take advantage of them.

Want to trade our USD/JPY forex analysis and predictions? Here’s a list of forex brokers in Japan to check out.

Christopher Lewis has been trading Forex and has over 20 years experience in financial markets. Chris has been a regular contributor to Daily Forex since the early days of the site. He writes about Forex for several online publications, including FX Empire, Investing.com, and his own site, aptly named The Trader Guy. Chris favours technical analysis methods to identify his trades and likes to trade equity indices and commodities as well as Forex. He favours a longer-term trading style, and his trades often last for days or weeks.

Source link

Read More
5 11, 2025

8 Ways Berberine Can Support Weight Loss and Metabolic Health Naturally

By |2025-11-05T19:18:18+02:00November 5, 2025|Dietary Supplements News, News|0 Comments


Key Takeaways

  • Berberine is a versatile supplement with benefits for blood sugar regulation, heart health, liver function, and weight management.
  • Some studies suggest that doses of around 500 mg, administered two to three times daily, were effective for specific conditions.
  • Always consult your healthcare provider before using supplements, especially if you’re taking prescription medications.

Berberine, a compound found in herbs like barberry and goldenseal, has gained popularity for its potential to support weight, blood sugar, and heart health naturally. Initial research appears promising, but additional studies are needed to confirm the benefits.

1. May Support Weight Loss

  • A 2020 review found that berberine supplements may moderately decrease weight, body mass index (BMI), waist size, and inflammation markers.
  • Some call it “nature’s Ozempic,” though it works differently from prescription medications.
  • The NCCIH notes that while berberine may offer small weight loss benefits, current studies are limited and more high-quality research is needed.
  • Lifestyle changes, including diet and exercise, are essential for achieving real results.

2. Can Help Control Blood Sugar

  • Research involving over 3,000 people shows that berberine lowered fasting blood sugar and hemoglobin A1c without causing low blood sugar (hypoglycemia).
  • It may improve insulin sensitivity, but absorption can vary, and some forms of berberine may actually have higher toxicity.

3. Has Cholesterol-Lowering Effects

  • Studies show berberine reduced low-density lipoprotein (LDL, or “bad”) cholesterol by 25%, triglycerides by 35%, and total cholesterol by 29%.
  • It may be a valuable add-on for those who cannot tolerate statins, though not a replacement.

4. May Help Improve Polycystic Ovary Syndrome (PCOS)

  • Berberine may help manage insulin resistance associated with PCOS, thereby improving blood sugar control and ovulation rates.
  • Early studies are promising, but further research is needed to provide conclusive evidence of its effectiveness.

5. Helps Lower Blood Pressure

  • Berberine helped reduce systolic blood pressure (the top number).
  • It was somewhat more effective when combined with lifestyle changes or blood pressure medications.
  • Conversely, some studies suggest limited evidence to support the use of berberine in controlling blood pressure.
  • Effective doses in studies ranged from 0.9 to 1.2 grams per day.

6. May Improve Gut Health

  • Berberine may positively influence your gut microbiota, supporting immune function and metabolism.
  • Effects vary by dose, and research continues on how it interacts with gut bacteria.

7. Can Support Liver Health

  • Berberine may protect the liver and support metabolic function, as well as cholesterol and insulin sensitivity.
  • Shows promise as an add-on therapy for fatty liver disease (MASLD/NAFLD).

8. May Have Anticancer Effects

  • Lab studies suggest berberine may inhibit cancer cell growth, reduce inflammation, and support conventional cancer treatments.
  • Research is ongoing, particularly in the areas of improving absorption and combining it with other therapies.

How to Take Berberine Safely

  • Typical dose: 500 mg, 2–3 times per day.
  • Take before meals for blood sugar support.
  • Avoid combining with specific medications—consult a healthcare professional.
  • Do not take more than directed.

Is Berberine Safe for Me?

  • Mild digestive issues: bloating, constipation, or diarrhea.
  • Potential interactions: diabetes or blood pressure medications, cyclosporine (an immunosuppressant).
  • Pregnant or breastfeeding: avoid berberine unless approved by a healthcare provider.
  • Berberine is not a substitute for the treatment prescribed by your healthcare provider.
  • In some cases, if your healthcare provider approves, berberine may be used in conjunction with other treatments and lifestyle changes.
  • However, it should never replace your recommended treatment plan.
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

  1. Asbaghi O, Ghanbari N, Shekari M, et al. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2020;38:43-49. doi:10.1016/j.clnesp.2020.04.010

  2. National Center for Complementary and Integrative Health. Berberine and weight loss: what you need to know.

  3. Ohio State University. Does berberine really help with weight loss?

  4. Xie W, Su F, Wang G, et al. Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis. Front Pharmacol. 2022;13:1015045. doi:10.3389/fphar.2022.1015045

  5. Utami AR, Maksum IP, Deawati Y. Berberine and its study as an antidiabetic compound. Biology (Basel). 2023;12(7):973. doi:10.3390/biology12070973

  6. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344-1351. doi:10.1038/nm1135

  7. Koppen LM, Whitaker A, Rosene A, et al. Efficacy of berberine alone and in combination for the treatment of hyperlipidemia: a systematic review. J Evid Based Complementary Altern Med. 2017;22(4):956-968. doi:10.1177/2156587216687695

  8. Yang L, Zhu W, Zhang X, et al. Efficacy and safety of berberine for several cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2023;112:154716. doi:10.1016/j.phymed.2023.154716

  9. Ionescu OM, Frincu F, Mehedintu A, et al. Berberine—a promising therapeutic approach to polycystic ovary syndrome in infertile/pregnant women. Life (Basel). 2023;13(1):125. doi:10.3390/life13010125

  10. Li MF, Zhou XM, Li XL. The effect of berberine on polycystic ovary syndrome patients with insulin resistance (PCOS-IR): a meta-analysis and systematic review. Evid Based Complement Alternat Med. 2018;2018:2532935. doi:10.1155/2018/2532935

  11. Zamani M, Zarei M, Nikbaf-Shandiz M, et al. The effects of berberine supplementation on cardiovascular risk factors in adults: a systematic review and dose-response meta-analysis. Front Nutr. 2022;9:1013055. doi:10.3389/fnut.2022.1013055

  12. MedlinePlus. Berberine.

  13. Suadoni MT, Atherton I. Berberine for the treatment of hypertension: a systematic review. Complement Ther Clin Pract. 2021;42:101287. doi:10.1016/j.ctcp.2020.101287.

  14. Zhang M, Feng L, Li J, et al. Therapeutic potential and mechanisms of berberine in cardiovascular disease. Curr Pharmacol Rep. 2016;2(6):281–292. doi:10.1007/s40495-016-0070-1.

  15. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823-1836. doi:10.1042/BCJ20160510

  16. Yang F, Gao R, Luo X, et al. Berberine influences multiple diseases by modifying gut microbiota. Front Nutr. 2023;10:1187718. doi:10.3389/fnut.2023.1187718

  17. Koperska A, Wesołek A, Moszak M, Szulińska M. Berberine in non-alcoholic fatty liver disease—a review. Nutrients. 2022;14(17):3459. doi:10.3390/nu14173459

  18. Nie Q, Li M, Huang C, et al. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. J Transl Med. 2024;22:225. doi:10.1186/s12967-024-05011-2

  19. Almatroodi SA, Alsahli MA, Rahmani AH. Berberine: an important emphasis on its anticancer effects through modulation of various cell signaling pathways. Molecules. 2022;27(18):5889. doi:10.3390/molecules27185889

  20. Memorial Sloan Kettering Cancer Center. Berberine.

By Karen Berger, PharmD

Karen Berger, PharmD, is a community pharmacist and medical writer/reviewer.



Source link

Read More
5 11, 2025

ADA Price Faces Extended Weakness as Sellers Retain Control

By |2025-11-05T19:12:18+02:00November 5, 2025|Crypto News, News|0 Comments

  • ADA struggles below key EMAs, signaling sustained bearish market control.
  • Futures open interest drop shows fading trader confidence and reduced leverage.
  • Continuous exchange outflows highlight weak accumulation and liquidity decline.

Cardano (ADA) continues to face bearish pressure as the cryptocurrency struggles to hold above the $0.49 support zone. The asset has maintained a downward trajectory for several weeks, with sellers dominating short-term momentum. 

ADA currently trades around $0.534, remaining well below key moving averages. The persistent weakness reflects a broader market slowdown, as traders exit leveraged positions and sentiment cools across altcoins.

Sustained Downtrend and Resistance Clusters

ADA has been trading below its 20, 50, 100, and 200-EMA levels, underscoring sustained bearish momentum. Each rebound attempt toward the $0.60–$0.65 …

Read The Full Article Cardano Price Prediction: ADA Price Faces Extended Weakness as Sellers Retain Control On Coin Edition.

Source link

Read More
5 11, 2025

Facts About Lung Cancer Screening

By |2025-11-05T18:49:18+02:00November 5, 2025|Fitness News, News|0 Comments

November is Lung Cancer Awareness Month.

Lung cancer has been the leading cause of cancer death in the United States for many years. And it accounts for about 1 in 5 of all cancer deaths throughout the country. In fact, more Americans die from lung cancer than from breast, prostate and colon cancer combined.

The American Cancer Society (ACS) estimates that about 125,000 Americans will die from lung cancer this year — and about 60,000 of those will be women.

Smoking is still the leading cause of lung cancer, with the ACS estimating that tobacco use causes about 8 out of 10 lung cancer cases.

But there’s some good news, too. New cases of lung cancer have decreased by an average of 2.4% each year according to the latest statistics. And death rates have fallen an average of 4.2% per year over the last decade.

Anti-smoking efforts have helped many Americans quit smoking or, better yet, never start. And lung cancer treatments have become much more effective over time.

One more factor helps account for these improvements: lung cancer screening for people at high risk. Researchers estimate that lung cancer screening could reduce the lung cancer death rate by up to 20%.

Here are some answers to frequently asked questions about lung cancer screening.

What is lung cancer screening?

In general, healthcare providers (HCPs) use screening tests to check for disease in healthy people who don’t have symptoms. The goal of screening is to find disease in its early stages, when treatment is most likely to be effective.

Lung cancer screening consists of a low-dose computed tomography (LDCT) scan of the lungs to look for lung cancer. This screening is currently recommended only for people at high risk for developing lung cancer.

To do this fast and painless test, you lie on a table that moves through a CT scanner to create clear images of your lungs.

Read: Lung Cancer Symptoms >>

Who should get screened?

The U.S. Preventive Services Task Force (USPSTF), a group that reviews scientific evidence to make patient-care recommendations, issued their most current recommendations in 2021. They recommend annual lung cancer screening for people who meet all of these requirements:

  • Are between the ages of 50 and 80
  • Have a smoking history of at least 20 pack years (the number of cigarette packs smoked per day multiplied by the number of years you’ve smoked)
  • Still smoke or have quit smoking within the past 15 years

Compared to previous versions, the USPSTF’s current guidelines lowered the age to start screening from 55 to 50 and dropped the minimum number of pack years from 30 to 20.

These changes significantly increased the number of women — especially Black women — who are considered high risk for lung cancer.

The ACS also has a lung cancer screening guideline. It has one important difference from the USPSTF guideline: The ACS recommends yearly scans regardless of how long ago you stopped smoking.

What is a “pack year”?

Scientists who study tobacco use the term “pack year” to measure how much people have smoked over time. Multiply the number of cigarette packs you’ve smoked per day by the number of years you’ve smoked. That’s your pack year.

If you smoked two packs a day for 10 years, that’s 20 pack years, which means you’re eligible for lung cancer screening. If you smoked one pack a day for 15 years, that’s 15 pack years and below the 20 pack-year threshold for screening.

Why can’t we screen everyone for lung cancer, even people who are not at high risk?

All screening tests carry the potential for both benefits and risks. That’s why you and your HCP should discuss your personal history and whether you should be screened for lung cancer. Shared decision-making means reviewing this information and creating a plan for your care together.

It’s important to note that smoking is currently the only risk factor for lung cancer that current screening guidelines consider.

Other potential causes of lung cancer like air pollution, radon exposure, secondhand smoke and genetic mutations are not included in today’s guidelines. Scientists are studying whether personalized screening approaches would identify more cases of lung cancer and potentially save more lives.

Read: How Shared Decision-Making Can Lead to Better Healthcare >>

What are the benefits of lung cancer screening?

The main benefit of lung cancer screening is the possibility of preventing death from lung cancer by catching it as soon as possible.

The American Lung Association (ALA) reports that lung cancer screening finds over half of lung cancer cases at an early stage when it’s more treatable.

One study found that only about 1 in 4 cases of lung cancers were found at an early stage without screening.

What are the risks of lung cancer screening?

Lung cancer screening is unlikely to miss cancer, but it can happen. This is known as a false negative result.

Test results that suggest a person has cancer when they don’t are called false positives. The ALA estimates that about 12-14% of a person’s first lung cancer screenings will have a false positive. But only about 6% of repeat scans show false positives because HCPscompare scans over time to look for changes.

One potential con to lung cancer screening is that it may also identify cancers that may never have caused harm if left alone. Rarely, lung cancers grow slowly and without causing symptoms. But any kind of lung cancer diagnosis means your HCP will likely recommend treatment. And treating cancer that is unlikely to harm you is called overtreatment.

Screening with LDCT also involves the use of low-dose radiation to capture images of your body. Over time, this radiation can cause health problems. But it’s important to know that LDCTs use much less radiation than standard CT scans.

What are some barriers to getting lung cancer screening?

According to the ALA’s State of Lung Cancer Report, only 16% of eligible people received lung cancer screening in 2022.

Various real-world barriers may discourage some eligible people from getting lung cancer screening. For example, some high-risk people may not know that they are eligible for lung cancer screening.

Some longtime or former smokers may also hold back from screening because of anxiety that they might have lung cancer or worries about the stigma facing people with lung cancer, that they somehow deserve to be sick.

Transportation issues and physical access to LDCT screening centers can also keep people from getting screened. This is especially true for people who live in rural communities.

If you’re eligible for lung cancer screening, cost is unlikely to be a barrier. Medicare and most private insurance plans cover lung cancer screening for eligible people at 100%. That means you likely won’t have any out-of-pocket cost — just like mammograms and other screening tests. However, any additional testing and follow-up scans between screenings may have a cost, such as a co-pay or deductible.

This educational resource was created with support from Merck.

From Your Site Articles

Related Articles Around the Web



Source link

Read More
Go to Top